Here are six updates on GI companies:
Osaka, Japan-based Takeda Pharmaceuticals entered into a strategic collaboration with Teaneck, N.J.-based NuBiyota for its microbial ecosystem therapeutic products. Takeda recently entered into a similar agreement with Finch Therapeutics over its inflammatory bowel disease treatment.
Memphis, Tenn.-based Baptist Memorial Health Care selected Weston, Fla.-based gMed's gGastro electronic health record system and its gInsignts performance measure platform as its primary procedure report writer. gMEd is a Modernizing Medicine company.
Tel Aviv, Israel-based RedHill Biopharma entered into a licensing agreement with Carcy, N.C.-based Entera Hill for its EnteraGam.
Senior Vice President and General Manager of Bridgewater, N.J.-based Salix Pharmaceuticals Mark McKenna talked to Becker's ASC Review about his dedication to revolutionizing gastroenterology and preventing GI diseases.
Laval, Canada-based Valeant Pharmaceuticals saw its share price drop 23 percent in March.
After a recent bacterial infection left five patients sick in an overseas facility, Sen. Patty Murray, D-Wash., wrote Tokyo-based Olympus requesting information proving their redesigned duodenoscopes were safe.